Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
166.41 USD
1.06%
Market Closed
Updated:
Apr 20, 2024
Abbvie Inc
Research & Development
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Research & Development Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
$-7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
$-6.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-12%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
$-4.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
$-3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
$-4.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-18%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Research & Development
$-1.6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-22%
|
See Also
What is Abbvie Inc's Research & Development?
Research & Development
-7B
USD
-7B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Research & Development amounts to -7B USD.
What is Abbvie Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-9%
-9%
Over the last year, the Research & Development growth was -8%. The average annual Research & Development growth rates for Abbvie Inc have been -4% over the past three years , -6% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
